We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA hit Torrance, California, OTC drugmaker Medical Chemical for a variety of violations seen at its facility, including inadequate cleaning and validating of equipment. Read More
The FDA came down on another Mylan facility with a warning letter — this time in Morgantown, West Virginia — for CGMP violations similar to those previously observed at other company plants. Read More
The FDA cited an Actavis Laboratories facility in Davie, Florida, over quality violations observed during a July inspection, including shortcomings with laser drilling procedures. Read More
The FDA slammed Hospira’s sterile drug facility in McPherson, Kansas, after finding the same violations during recent inspections that were flagged during earlier probes. Read More
Serious deficiencies in sterile drug production at Greenpark Compounding in Houston, Texas, may put patients at risk, the FDA said in a warning letter to the compounder. Read More
The FDA sent a warning letter listing a slew of violations to StemGenex Biologic Laboratories, following a January 16-26 inspection of its San Diego, California, facility. Read More